Tesamorelin Profile

Last updated: June 9, 2026

TL;DR

Tesamorelin is a synthetic GHRH analog approved by the FDA for HIV-associated lipodystrophy. Off-label, it is used for visceral fat reduction, abdominal slimming, and longevity stacking. Standard dose is 2 mg SubQ once daily, typically at bedtime. Effects: 15-20% reduction in visceral adipose tissue over 26 weeks, IGF-1 rise, and improved lipid profile. Best paired with a calorie-deficit diet for cosmetic fat loss results.

What is Tesamorelin?

Tesamorelin is a 44-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH). It binds the GHRH receptor in the anterior pituitary and triggers natural pulsatile growth hormone release. Unlike injecting exogenous HGH directly, tesamorelin works by stimulating the body own production system, which preserves the normal feedback loops and tends to produce a cleaner side-effect profile.

What is it actually approved for?

FDA approved in 2010 under the brand Egrifta for the reduction of visceral adipose tissue in HIV-infected patients with lipodystrophy. The clinical trial data showed 15-20% reduction in visceral fat over 26 weeks at 2 mg/day, with modest improvements in lipid markers. This is the only approved indication – all other uses are off-label.

How does it work?

Tesamorelin binds the GHRH receptor on somatotroph cells in the pituitary. This triggers the natural pulsatile release of growth hormone. The released GH circulates through the body, hits the liver, and stimulates IGF-1 production. Elevated IGF-1 and pulsatile GH drive the metabolic effects: visceral fat oxidation, modest lean mass preservation, improved sleep architecture, and slow tissue repair. The drug half-life is about 26-38 minutes, but the resulting GH and IGF-1 effects last hours.

What dose should you run?

Standard protocol matches the clinical trials:

• 2 mg subcutaneously, once daily
• Inject 60-90 minutes before bed to align with the natural GH pulse
• Reconstitute the powder with sterile or bacteriostatic water just before injection

Some researchers run 1 mg/day for budget reasons or for sub-clinical lipodystrophy use. Going above 2 mg does not produce proportional benefit and increases the chance of IGF-1 overshooting safe limits. See our reconstitution guide for mixing math.

How long should you cycle?

26 weeks is the standard clinical duration. Most off-label users run 12-16 week cycles followed by 8-12 weeks off to let IGF-1 normalize. Continuous use beyond 6 months has been studied and remains safe, but IGF-1 should be tracked. Receptor desensitization is not a major concern – tesamorelin maintains its effect even over 12+ month protocols in HIV patients.

How fast does fat loss happen?

Visible visceral fat reduction takes 8-16 weeks. Waist circumference drops 2-4 cm typically. Subcutaneous fat (the kind you pinch) responds less – tesamorelin is specifically targeted at the visceral depot around the organs. This makes it a precise tool for the abdominal fat that resists conventional dieting. Pairing tesamorelin with a 300-500 kcal/day deficit accelerates visible results without aggressive cardio.

What about lean mass?

Modest preservation, not significant gain. Tesamorelin produces a 1-2% increase in lean body mass typically, mostly from connective tissue and skeletal muscle protein synthesis driven by elevated IGF-1. It is not a hypertrophy compound – the gains are not visible in mirror terms. Best paired with resistance training for whatever lean mass benefit you can capture.

What bloodwork should you track?

Important panel for tesamorelin use:

• IGF-1 – the main biomarker, expect 60-150% rise from baseline
• Fasting glucose and HbA1c – GH can mildly raise both
• Lipid panel – typically improves on tesamorelin
• Liver enzymes ALT/AST – baseline check, usually unchanged

Target IGF-1 ceiling of 350 ng/mL for off-label users. Going above 400 ng/mL increases the risk of carpal tunnel, joint stiffness, and insulin resistance. We covered the full peptide bloodwork approach in our BPC-157 guide – same monitoring principles apply.

What are the side effects?

From the published trials and broader off-label reports:

• Injection-site redness and itching (most common)
• Joint or muscle aches in the first 2-3 weeks
• Mild glucose elevation (small but measurable)
• Occasional carpal tunnel symptoms at high IGF-1 levels
• Rare allergic reaction to the diluent or excipients

Severe side effects are rare. The compound is generally well tolerated even on long protocols. Discontinue if joint pain becomes significant – usually a sign IGF-1 is running too high.

Can you stack it with other peptides?

Yes. Common stacks:

• Tesamorelin + Ipamorelin – adds a GHRP for stronger pulses, deeper sleep
• Tesamorelin + AOD-9604 – layers two fat-loss mechanisms, target both visceral and subcutaneous depot
• Tesamorelin + BPC-157 – the joint recovery + fat loss combo

Avoid stacking tesamorelin with CJC-1295 + DAC simultaneously – both saturate the GHRH receptor and produce no additional benefit.

How does it compare to direct HGH?

Tesamorelin produces pulsatile GH that matches the natural physiology. Direct HGH injection produces a sustained high level that ignores the normal feedback loops. The advantages of tesamorelin: lower cost per effective dose, lower carpal tunnel risk, no significant water retention, no shutdown of natural GH production. Direct HGH wins on raw potency but the trade-offs are larger.

How do you reconstitute and store it?

Tesamorelin ships as a lyophilized white powder, usually 5 mg or 10 mg per vial. Reconstitute with sterile water – 2 mL of water in a 10 mg vial gives 5 mg/mL or 1 mg per 0.2 mL (so 0.4 mL = 2 mg). Use within 30 days refrigerated. Lyophilized vials store in the freezer for 2+ years.

Is Tesamorelin legal in Canada?

Tesamorelin is approved by Health Canada for HIV-associated lipodystrophy under the brand Egrifta. Off-label use requires a prescription. Research-grade tesamorelin is sold for non-human use under research chemical guidelines. Federal classification is at the Health Canada Drugs and Health Products page.

Sources

• Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. J Clin Endocrinol Metab, 2010.
• Stanley TL, et al. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA, 2014.
• Health Canada Egrifta product monograph, 2024 edition.